Essential thrombocythaemia: challenges and evidence-based management
In: British journal of haematology, Jg. 130 (2005-07-21), Heft 2
Online
unknown
Zugriff:
Essential thrombocythaemia was first described over 70 years ago. This condition is dominated by thrombotic and haemorrhagic complications and, in the long-term, by risk of transformation to myelofibrosis and/or acute leukaemia. However, it is heterogeneous both clinically and biologically. Here, a review of current concepts in disease aetiology and management is offered with reference to recent focused reviews where appropriate. In addition, five specific areas are discussed in detail: the role of the trephine biopsy, the disease entity prefibrotic myelofibrosis; the recently described Janus kinase 2 (JAK2) mutations; the leukaemogenicity of hydroxyurea (hydroxycarbamide); and lastly, the implications of the results of the Medical Research Council Primary Thrombocythaemia 1 study are explored.
Titel: |
Essential thrombocythaemia: challenges and evidence-based management
|
---|---|
Autor/in / Beteiligte Person: | Harrison, Claire N. |
Link: | |
Zeitschrift: | British journal of haematology, Jg. 130 (2005-07-21), Heft 2 |
Veröffentlichung: | 2005 |
Medientyp: | unknown |
ISSN: | 0007-1048 (print) |
Schlagwort: |
|
Sonstiges: |
|